1 / 8

2013 Annual Shareholder Meeting Dwight Babcock, CEO

2013 Annual Shareholder Meeting Dwight Babcock, CEO. Innovative Solutions Begins With A Great Team. Fred Swindler Bill Cavanagh Brien Ragle Krista Cline Dale Boyce Clay O’Laughlin. State of Prostate Cancer Treatments. Brachytherapy External Beam Robotic Surgery

freira
Download Presentation

2013 Annual Shareholder Meeting Dwight Babcock, CEO

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 2013 Annual Shareholder Meeting Dwight Babcock, CEO

  2. Innovative SolutionsBegins With A Great Team Fred Swindler Bill Cavanagh Brien Ragle Krista Cline Dale Boyce Clay O’Laughlin

  3. State of Prostate Cancer Treatments Brachytherapy External Beam Robotic Surgery Proton Beam Task Force Report

  4. New Product Initiatives Gliobastoma Brain Cancer Metastatic Brain Cancer Meningioma Brain Tumors Head and Neck Cancer Non Small Cell Lung Cancer Gynecologic Cancer

  5. Brachytherapy Competition Prostate – Consolidation of I-125 & P-103 Brain Cancers and Tumors – None GliaSite Balloon Radiation Therapy – None Lung Cancer – I-125 sutured seeds No Mesh Gynecologic Cancer - None *Published Papers Are Needed Prior To General Adoption

  6. Pharma Model FDA Approval: 2 years Product development and pre-human testing: 5 years Human Clinical Trials: 5 years Adoption IsoRay Prostate Model Product development 510(k) FDA Approval 1-2 years Early Adopters Data Published Papers 5-6 years Wider Scale Adoption IsoRay New Product Model Product development 510(k) FDA Approval 1-2 years Early Adopters Data Published Papers 1-3 years Wider Scale Adoption

  7. Current Protocols Cornell Weill – Lung Cancer Cornell Weill – Metastatic Brain Cancer Archibold Medical – Lung Cancer MD Anderson – Intermediate Prostate Cancer Sylvestor – Dual Therapy Prostate Cancer Cole – Mono Therapy Prostate Cancer Barrows – Meningioma Brain Tumors

More Related